Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles

Joshua Owen, Conor McEwan, Heather Nesbitt, Phurit Bovornchutichai, Raymond Averre, Mark Borden, Anthony McHale, John F Callan, Eelanor Stride

Research output: Contribution to journalArticle

12 Citations (Scopus)
2 Downloads (Pure)


Hypoxia has been shown to be a key factor inhibiting the successful treatment of solid tumours. Existing strategies for reducing hypoxia, however, have shown limited efficacy and/or adverse side effects. The aim of this study was to investigate the potential for reducing tumour hypoxia using an orally delivered suspension of surfactant-stabilised oxygen nanobubbles. Experiments were carried out in a mouse xenograft tumour model for human pancreatic cancer (BxPc-3 cells in male SCID mice). A single dose of 100 μL of oxygen saturated water, oxygen nanobubbles or argon nanobubbles was administered via gavage. Animals were sacrificed 30 minutes post-treatment (3 per group) and expression of hypoxiainducible-factor-1α (HIF1α) protein measured by real time quantitative polymerase chain reaction and Western blot analysis of the excised tumour tissue. Neither the oxygen saturated water nor argon nanobubbles produced a statistically significant change in HIF1α expression at the transcriptional level. In contrast, a reduction of 75% and 25% in the transcriptional and translational expression of HIF1α respectively (p
Original languageEnglish
Pages (from-to)e0168088
JournalPLoS ONE
Issue number12
Publication statusPublished - 30 Dec 2016


  • Nanobubbles
  • Oxygen
  • Hypoxia
  • HIF-1 alpha

Fingerprint Dive into the research topics of 'Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles'. Together they form a unique fingerprint.

  • Cite this

    Owen, J., McEwan, C., Nesbitt, H., Bovornchutichai, P., Averre, R., Borden, M., ... Stride, E. (2016). Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles. PLoS ONE, 11(12), e0168088.